Mechanisms of PARP Inhibitor Resistance: From Replication Gap Biology and Transcription–Replication Conflicts to PROTAC ‐Based Next‐Generation Strategies
Environmental and Molecular Mutagenesis · 2026
DOI: 10.1002/em.70076 ↗At a glance
Übersichtsarbeit in Environmental and Molecular Mutagenesis, 2026. Written by Abinawanto and 1 co-authors. Institution: Department of Biology, Faculty of Mathematics and Natural Sciences, Universitas Indonesia, Depok, Indonesia. Major MEDLINE topics: Poly(ADP-ribose) Polymerase Inhibitors, Drug Resistance, Neoplasm, DNA Replication, Transcription, Genetic. 29 references. The full text is freely available in PubMed Central.
Abstract (original language)
Poly(ADP‐ribose) polymerase (PARP) inhibitors (PARPi) have transformed precision oncology by exploiting synthetic lethality in homologous recombination (HR)‐deficient cancers, with multiple FDA‐approved agents targeting BRCA1/2 ‐mutant tumors. Despite initial efficacy, resistance inevitably emerges, limiting long‐term clinical benefit. This review synthesizes emerging mechanistic insights into PARPi response and resistance. Recent evidence reframes PARP inhibition cytotoxicity through a transcription–replication conflict model and identifies single‐stranded DNA gaps as the primary lethal lesion in HR‐deficient cells, rather than double‐strand breaks. These findings suggest that resistance reflects restoration of replication gap suppression or resolution of transcription–replication stress. We further highlight DNA ligase III as a collateral vulnerability in 53BP1 ‐deficient resistant tumors, and discuss proteolysis‐targeting chimera (PROTAC)‐based PARP1 degraders as a strategy to overcome resistance and induce alternative cell death pathways. Established resistance mechanisms—including BRCA1/2 reversion mutations, shieldin complex loss, RAD51 hyperactivation, and pharmacokinetic alterations—are reconsidered within this updated framework. Combination strategies with ATR inhibitors show promising clinical activity in PARPi‐resistant HR‐deficient ovarian cancer. Finally, we propose an integrated biomarker framework combining HRD scar assays, functional RAD51 foci analysis, replication gap profiling, and circulating tumor DNA (ctDNA) monitoring to enable dynamic resistance tracking.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Biology, Faculty of Mathematics and Natural Sciences, Universitas Indonesia, Depok, Indonesia.
- The Indonesian Food and Drug Authority (BPOM), Jakarta, Indonesia.
ORCID profiles: Abinawanto, Alfi Sophian
Cite
APA
Abinawanto, & Sophian, A. (2026). Mechanisms of PARP Inhibitor Resistance: From Replication Gap Biology and Transcription–Replication Conflicts to PROTAC ‐Based Next‐Generation Strategies. Environmental and Molecular Mutagenesis. https://doi.org/10.1002/em.70076
Vancouver
Abinawanto, Sophian A. Mechanisms of PARP Inhibitor Resistance: From Replication Gap Biology and Transcription–Replication Conflicts to PROTAC ‐Based Next‐Generation Strategies. Environmental and Molecular Mutagenesis. 2026. doi:10.1002/em.70076
BibTeX
@article{Abinawanto2026,
author = {Abinawanto and Sophian, Alfi},
title = {Mechanisms of PARP Inhibitor Resistance: From Replication Gap Biology and Transcription–Replication Conflicts to PROTAC ‐Based Next‐Generation Strategies},
journal = {Environmental and Molecular Mutagenesis},
year = {2026},
doi = {10.1002/em.70076}
}
EUVIMED